Mark Haden
Corporate Officer/Principal bei CLEARMIND MEDICINE INC.
Vermögen: 160 $ am 30.04.2024
Profil
Mark Haden is currently the Vice President of Business Development at Clearmind Medicine, Inc. He previously worked as the Director of Clinical Trials at Psygen Labs, Inc. from 2021 to 2022 and as the Executive Director at Multidisciplinary Association for Psychedelic Studies Canada from 2017 to 2021.
Haden received his undergraduate and graduate degrees from the University of British Columbia.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
CLEARMIND MEDICINE INC.
0,00% | 31.10.2023 | 133 ( 0,00% ) | 160 $ | 30.04.2024 |
Aktive Positionen von Mark Haden
Unternehmen | Position | Beginn |
---|---|---|
CLEARMIND MEDICINE INC. | Corporate Officer/Principal | 01.07.2021 |
Ehemalige bekannte Positionen von Mark Haden
Unternehmen | Position | Ende |
---|---|---|
Psygen Labs, Inc.
Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Corporate Officer/Principal | 01.03.2022 |
Ausbildung von Mark Haden
University of British Columbia | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CLEARMIND MEDICINE INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Psygen Labs, Inc.
Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Health Technology |